01 Growth of Ophthalmology Clinics as Key End-Users for Premium Ophthalmic Viscosurgical DevicesOphthalmology clinics are emerging as major end-users of premium ophthalmic viscosurgical devices (OVDs), driven by the increasing number of solo ophthalmology practices. These clinics are adopting advanced OVDs to enhance surgical precision and improve patient outcomes, particularly in premium intraocular lens (IOL) implantation.According to the American Academy of Ophthalmology, as of 2022, there were approximately 18,000 practicing ophthalmologists in the U.S., with nearly 26% operating independently in solo practices.This rise in independent clinics reflects the growing demand for specialized, high-quality ophthalmic care, further fueling the adoption of advanced OVDs.
01 Increasing Adoption of Ovds in Corneal Grafting SurgeriesThe increasing incidence of keratoconus and Fuchs' dystrophy, particularly penetrating keratoplasty (PK) and endothelial keratoplasty (EK), has increased the demand for corneal grafting surgeries. OVDs are important in these procedures as they protect the donor graft by stabilizing the anterior chamber and minimizing endothelial cell loss.Thus, the increasing preference for high-quality OVDs in corneal grafting surgeries underscores their crucial role in corneal transplant, further propelling market demand.
01 Competition from Alternative Breastfeeding SolutionsA significant challenge in the ophthalmic viscosurgical devices (OVDs) market, particularly with cohesive OVDs, is their potential to cause intraocular pressure (IOP) spikes if not fully removed after surgery. This issue is especially critical in cataract and glaucoma procedures, where maintaining optimal pressure levels is essential for post-surgical recovery.Residual cohesive OVDs can obstruct aqueous humor outflow, leading to transient IOP elevations that may result in complications such as optic nerve injury, particularly in glaucoma patients. Although cohesive OVDs are generally preferred for their ease of removal, studies indicate that even minimal traces left behind can contribute to IOP fluctuations.This safety concern has limited the widespread adoption of cohesive OVDs, particularly in glaucoma surgeries, where precise pressure control is crucial. As a result, the market faces challenges in balancing the benefits of cohesive OVDs with the need for enhanced safety measures to prevent post-operative pressure spikes.
01 Expanding Product Range for Sensitive Skin and Medical-Grade SolutionsThe demand for ophthalmic viscosurgical devices (OVDs) with superior biocompatibility is rising, particularly in vitreoretinal surgeries where longer intraocular retention is necessary. In procedures such as retinal detachment repair and macular hole surgery, minimizing inflammation and cellular toxicity is critical to ensuring successful outcomes. To address these needs, the market is witnessing innovations in viscoadaptive OVDs that provide extended retention while reducing postoperative complications.Such advancements cater to the growing need for safer, long-lasting OVDs, improving surgical precision and patient recovery in delicate retinal procedures.
April 2026 Alcon strengthened its cataract surgery portfolio by enhancing ophthalmic viscosurgical devices with improved cohesive and dispersive properties to support safer and more efficient intraocular procedures.
February 2026 Bausch + Lomb expanded its ophthalmic surgery portfolio by launching advanced OVD solutions engineered to improve endothelial protection and optimize surgical outcomes in cataract and anterior segment surgeries.
September 2025 Carl Zeiss Meditec expanded its ophthalmic surgical ecosystem through enhanced integration of OVD-compatible technologies with advanced cataract surgery platforms, improving procedural workflow and precision.
May 2025 Rayner strengthened its ophthalmic product portfolio by expanding solutions supporting cataract surgery, including advanced ophthalmic viscosurgical devices designed to enhance intraoperative performance and patient outcomes.